Cancer Genetics Inc (NASDAQ:CGIX) traded up 9.1% on Monday . The stock traded as high as $0.12 and last traded at $0.12, 1,471,611 shares changed hands during trading. A decline of 28% from the average session volume of 2,031,043 shares. The stock had previously closed at $0.11.

The company has a 50 day simple moving average of $0.15 and a two-hundred day simple moving average of $0.21. The company has a debt-to-equity ratio of 0.24, a quick ratio of 0.36 and a current ratio of 0.36.

Cancer Genetics (NASDAQ:CGIX) last issued its quarterly earnings data on Monday, May 20th. The medical research company reported ($0.08) earnings per share for the quarter. Cancer Genetics had a negative return on equity of 175.72% and a negative net margin of 77.28%. The company had revenue of $6.84 million for the quarter.

Hedge funds and other institutional investors have recently modified their holdings of the business. Virtu Financial LLC bought a new position in shares of Cancer Genetics during the first quarter valued at approximately $48,000. Geode Capital Management LLC grew its stake in shares of Cancer Genetics by 106.6% during the fourth quarter. Geode Capital Management LLC now owns 221,803 shares of the medical research company’s stock valued at $53,000 after buying an additional 114,448 shares during the last quarter. Finally, Renaissance Technologies LLC grew its stake in shares of Cancer Genetics by 38.4% during the second quarter. Renaissance Technologies LLC now owns 2,777,125 shares of the medical research company’s stock valued at $453,000 after buying an additional 769,896 shares during the last quarter. 11.59% of the stock is currently owned by institutional investors.

Cancer Genetics Company Profile (NASDAQ:CGIX)

Cancer Genetics, Inc develops, commercializes, and provides molecular and biomarker-based tests and services in the United States, Europe, and Asia. Its tests enable physicians to personalize the clinical management of each individual patient by providing genomic information to diagnose, monitor, and inform cancer treatment; and enable biotech and pharmaceutical companies involved in oncology and immuno-oncology trials to select candidate populations and reduce adverse drug reactions by providing information regarding genomic factors influencing subject responses to therapeutics.

Featured Article: What strategies should day traders use to execute a trade?

Receive News & Ratings for Cancer Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cancer Genetics and related companies with MarketBeat.com's FREE daily email newsletter.